Only a minimal amount of Rituximab crosses the placenta during the first trimester but more and more will cross as the pregnancy progresses so it is unlikely that the baby has been exposed to the Rituximab.  Thirteen cases of Rituximab being given to pregnant women have been reported.  Another 10 cases  are mentioned in an unpublished safety report.  All of the babies have been healthy and not had any deformities.  In addition, studies in monkeys show no teratogenic effects of Rituximab. 

Dr Andrea Milbourne, one of gynecologists here at MD Anderson, collects information on pregnant patients who are receiving therapy for their cancer when they get pregnant so we can collect data to help future women through their pregnancies.